ArticleJournal of veterinary science2010
Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43.
Article in Journal of veterinary science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 107 citations in OpenAlex.
- Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections.Clinical lung cancer · 2024Article
- Terpenes and cannabidiol against human corona and influenza viruses-Anti-inflammatory and antiviral in vitro evaluation.Biotechnology reports (Amsterdam, Netherlands) · 2024Article
- The role of cross-reactive immunity to emerging coronaviruses: Implications for novel universal mucosal vaccine design.Saudi medical journal · 2023Review
- One for all-human kidney Caki-1 cells are highly susceptible to infection with corona- and other respiratory viruses.Journal of virology · 2023Article
- Immunological changes in a cohort of COVID-19 survivors: Mansoura University experience.F1000Research · 2023Article
- Article
- The correlation between IgM and IgG antibodies with blood profile in patients infected with severe acute respiratory syndrome coronavirus.Clinical and molecular allergy : CMA · 2022Article
- Nanomaterials and metal-organic frameworks for biosensing applications of mutations of the emerging viruses.Analytical biochemistry · 2022Review
- Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.Molecular immunology · 2022Article
- Analytical performances of different diagnostic methods for SARS-CoV-2 virus - A review.Sensors international · 2022Review
- Diagnostic accuracy of antibody-based rapid diagnostic tests in detecting coronavirus disease 2019: systematic review.Archives of medical science : AMS · 2022Review
- Review
- Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT).Annals of medicine · 2021Article
- Validation of rapid antibody (IgG-IgM) test kit for SARS-CoV-2 infection in Qatar.Journal of public health research · 2021Article
- Development and clinical evaluation of a rapid antibody lateral flow assay for the diagnosis of SARS-CoV-2 infection.BMC infectious diseases · 2021Article
- Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations.Current issues in molecular biology · 2021Review
- Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Article
- Design and Numerical Analysis of a Graphene-Coated SPR Biosensor for Rapid Detection of the Novel Coronavirus.Sensors (Basel, Switzerland) · 2021Article
- SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome (SARS) is a life-threatening disease for which accurate diagnosis is essential. Although many tools have been developed for the diagnosis of SARS, false-positive reactions in negative sera may occur because of cross-reactivity with other coronaviruses. We have raised polyclonal and monoclonal antibodies (Abs) using a recombinant form of the SARS virus nucleocapsid protein. Cross-reactivity of these anti-SARS Abs against human coronavirus (HCoV) 229E and HCoV OC43 were determined by Western blotting. The Abs produced reacted with recombinant SARS virus nucleocapsid protein, but not with HCoV 229E or HCoV OC43.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.